BioSpace News Archive

Avelead announced that it has executed an agreement to implement its automated charge reconciliation solution RevID with its first MEDITECH electronic health record customer.

ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that it has been engaged by Orion BioTech, Inc., a medical device company based in Taipei, Taiwan, to identify candidates interested in out-licensing Orion developmental products.

Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

Stryker (NYSE:SYK) today announced the launch of its EasyFuse™ Dynamic Compression System.

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company will participate at Redeye Growth Day on June 2, 2022 at 09:10 CEST.

Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters that were presented during the Digestive Disease Week ® (DDW), May 21-24, 2022 in San Diego.

GrowLab™ Pharmaceuticals PLC (“GrowLab”) recorded 96% Clinical Diabetes Remission following independent clinical trials of its phytocannabinoids based therapeutic Comacadine® curated and synthesised from its proprietary DNA-specific strains of medical cannabis in treatment of Diabetes Mellitus.

Alphatec Holdings Inc. (Nasdaq: ATEC) announced that it will host an Investor Day at the Company’s headquarters in Carlsbad, CA, today.

Anaconda Inc., provider of the world’s most popular data science platform, announced the appointment of Shahz Afzal as SVP of Marketing & Strategy, who comes from the AWS Marketplace division.

AlzeCure Pharma AB announced that it has received approval from the regulatory authorities in Sweden to initiate its clinical phase IIa study with the drug candidate ACD440 in patients with peripheral neuropathic pain.